{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal Chondrochymal",
            "NStudiesAvail": 430108,
            "NStudiesFound": 2,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 2,
            "FieldList": [
                  "BriefSummary",
                  "BriefTitle",
                  "CentralContactEMail",
                  "CentralContactName",
                  "CentralContactPhone",
                  "CentralContactPhoneExt",
                  "CentralContactRole",
                  "CollaboratorClass",
                  "CollaboratorName",
                  "CompletionDate",
                  "CompletionDateType",
                  "Condition",
                  "ConditionAncestorId",
                  "ConditionAncestorTerm",
                  "ConditionBrowseBranchAbbrev",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "BriefSummary": [
                              "This is a randomized, single-blind, parallel, active-controlled study to evaluate the efficacy and safety of bone marrow mesenchymal stem cells (BM-MSCs), Chondrochymal\u00ae, in subjects aged 40 to 80 with knee OA."
                        ],
                        "BriefTitle": [
                              "Chondrochymal\u00ae for Subjects With Knee Osteoarthritis (Knee OA)"
                        ],
                        "CentralContactEMail": [
                              "Cyrusyang@twbio-thera.com"
                        ],
                        "CentralContactName": [
                              "chun-yao yang, PhD"
                        ],
                        "CentralContactPhone": [
                              "+886 226956382"
                        ],
                        "CentralContactPhoneExt": [],
                        "CentralContactRole": [
                              "Contact"
                        ],
                        "CollaboratorClass": [
                              "INDUSTRY"
                        ],
                        "CollaboratorName": [
                              "A2 Healthcare Taiwan Corporation"
                        ],
                        "CompletionDate": [
                              "September 10, 2024"
                        ],
                        "CompletionDateType": [
                              "Anticipated"
                        ],
                        "Condition": [
                              "Osteoarthritis, Knee"
                        ],
                        "ConditionAncestorId": [
                              "D000001168",
                              "D000007592",
                              "D000009140",
                              "D000012216"
                        ],
                        "ConditionAncestorTerm": [
                              "Arthritis",
                              "Joint Diseases",
                              "Musculoskeletal Diseases",
                              "Rheumatic Diseases"
                        ],
                        "ConditionBrowseBranchAbbrev": [
                              "BC05",
                              "All",
                              "BC17"
                        ],
                        "NCTId": [
                              "NCT05027581"
                        ]
                  },
                  {
                        "Rank": 2,
                        "BriefSummary": [
                              "The Clinical trial is a phase I/IIa clinical study for treatment of knee osteoarthritis by intra-articular injection of bone marrow derived allogeneic mesenchymal stem cells. Primary endpoint of the study is safety of allogeneic BM-MSCs application on knee OA with single dose IA injection and the MTD. Secondary endpoint is the effect of allogeneic BM-MSCs transplantation including clinical and image observation since the MSCs have multi-lineage differentiation potential such as chondrocyte differentiation, anti-inflammation and immune-modulation."
                        ],
                        "BriefTitle": [
                              "Allogeneic Bone Marrow MSC Therapy for Knee Osteoarthritis"
                        ],
                        "CentralContactEMail": [],
                        "CentralContactName": [],
                        "CentralContactPhone": [],
                        "CentralContactPhoneExt": [],
                        "CentralContactRole": [],
                        "CollaboratorClass": [
                              "OTHER"
                        ],
                        "CollaboratorName": [
                              "Virginia Contract Research Organization Co., Ltd."
                        ],
                        "CompletionDate": [
                              "April 30, 2020"
                        ],
                        "CompletionDateType": [
                              "Actual"
                        ],
                        "Condition": [
                              "Knee Osteoarthritis"
                        ],
                        "ConditionAncestorId": [
                              "D000001168",
                              "D000007592",
                              "D000009140",
                              "D000012216"
                        ],
                        "ConditionAncestorTerm": [
                              "Arthritis",
                              "Joint Diseases",
                              "Musculoskeletal Diseases",
                              "Rheumatic Diseases"
                        ],
                        "ConditionBrowseBranchAbbrev": [
                              "BC05",
                              "All",
                              "BC17"
                        ],
                        "NCTId": [
                              "NCT03589287"
                        ]
                  }
            ]
      }
}